ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412

Its studies are mostly in Neoplasms, led by Tavotek Biotherapeutics.

Furthest: phase 1, since Sep 14, 20222 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tavotek Biotherapeutics22 open or runningphase 1since Sep 14, 2022Sep 14, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05548634 · 50 enrolled · United States
  2. Dec 30, 2024Phase 1 study in NeoplasmsNCT06761651 · 50 planned · China

TargetBeta

“A trispecific antibody targeting hepatocyte growth factor receptor (HGFR; c-Met), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF), ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06761651Neoplasms · China1RecruitingJan 1, 202650
NCT05548634Neoplasms · United States1Active, not recruitingDec 30, 202550

How it is read

Names in the registry

  • “TAVO412”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.